[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.194.190. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 3,254
Citations 0
Research Letter
May 8, 2019

Buprenorphine Treatment Divide by Race/Ethnicity and Payment

Author Affiliations
  • 1Department of Medicine, University of Michigan, School of Medicine, Ann Arbor
  • 2Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan
  • 3Institute for Health Policy and Innovation, Ann Arbor, Michigan
  • 4Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor
  • 5Department of Psychiatry, University of Michigan, School of Medicine, Ann Arbor
  • 6VA Ann Arbor Healthcare System, Ann Arbor, Michigan
JAMA Psychiatry. 2019;76(9):979-981. doi:10.1001/jamapsychiatry.2019.0876

Opioid mortality rates continue to increase throughout the United States1; however, growth in buprenorphine hydrochloride treatment for opioid use disorder (OUD) might be limited to communities with higher income and low percentages of racial/ethnic minorities.2 Buprenorphine, a partial opioid agonist, is 1 of 3 evidence-based medications for treating OUD and can legally be prescribed in office-based settings.

×